Key Takeaways
- • Audax Private Equity and Linden Capital Partners have agreed to sell StatLab Medical Products to Leica Biosystems, an operating company of Danaher Corporation (NYSE: DHR), in an all-cash transaction with undisclosed terms expected to close by year-end 2026.
- • StatLab, founded in 1976 and headquartered in McKinney, Texas, is a leading manufacturer of pre-analytical products across the anatomic pathology workflow, serving laboratories and OEM customers in the United States and Europe.
- • During five years of Audax and Linden ownership since 2021, StatLab expanded from a primarily U.S.-focused business into a global integrated manufacturer through nine strategic acquisitions, enhanced in-house production capabilities, and commercial function investments.
- • The acquisition strengthens Leica Biosystems' end-to-end anatomic pathology ecosystem, enabling the company to offer integrated solutions that help laboratories optimize workflows and operational efficiency.
- • Joe Bernardo, Chairman of StatLab and Linden Operating Partner, highlighted StatLab's transformation into "a stronger, more global, and more innovative company" during the private equity ownership period.
Summary
Audax Private Equity and Linden Capital Partners announced on July 14, 2026, an agreement to sell StatLab Medical Products to Leica Biosystems, a subsidiary of Danaher Corporation. The transaction, subject to customary closing conditions, is expected to close by the end of 2026. Deal terms remain undisclosed.
StatLab, established in 1976 and based in McKinney, Texas, specializes in manufacturing pre-analytical products spanning the complete anatomic pathology workflow. The company serves a diversified customer base including laboratories and original equipment manufacturers (OEMs) across the United States and Europe. Founded during an era of rapid healthcare diagnostics expansion, StatLab has built a reputation for quality products and customer service in the critical pre-analytical phase of laboratory testing.
During the five-year ownership period beginning in 2021, Audax and Linden executed a transformative strategy that repositioned StatLab from a primarily domestic business into a globally integrated manufacturer. The private equity sponsors invested in team expansion and commercial infrastructure while systematically enhancing in-house production capabilities. The partnership completed nine strategic acquisitions that broadened StatLab's self-manufacturing footprint and product portfolio across the anatomic pathology workflow. These investments drove organic growth acceleration and reinforced customer relationships through a vertically integrated operating model.
Joe Bernardo, StatLab's Chairman and Linden Operating Partner, commented that the partnership successfully executed its vision to build a "scaled, self-manufacturing platform spanning the anatomic pathology workflow." The acquisition by Leica Biosystems represents a strategic fit within Danaher's diversified life sciences and diagnostics portfolio, enabling Leica to expand its end-to-end anatomic pathology ecosystem and deliver integrated solutions designed to improve laboratory operational efficiency.
StatLab, established in 1976 and based in McKinney, Texas, specializes in manufacturing pre-analytical products spanning the complete anatomic pathology workflow. The company serves a diversified customer base including laboratories and original equipment manufacturers (OEMs) across the United States and Europe. Founded during an era of rapid healthcare diagnostics expansion, StatLab has built a reputation for quality products and customer service in the critical pre-analytical phase of laboratory testing.
During the five-year ownership period beginning in 2021, Audax and Linden executed a transformative strategy that repositioned StatLab from a primarily domestic business into a globally integrated manufacturer. The private equity sponsors invested in team expansion and commercial infrastructure while systematically enhancing in-house production capabilities. The partnership completed nine strategic acquisitions that broadened StatLab's self-manufacturing footprint and product portfolio across the anatomic pathology workflow. These investments drove organic growth acceleration and reinforced customer relationships through a vertically integrated operating model.
Joe Bernardo, StatLab's Chairman and Linden Operating Partner, commented that the partnership successfully executed its vision to build a "scaled, self-manufacturing platform spanning the anatomic pathology workflow." The acquisition by Leica Biosystems represents a strategic fit within Danaher's diversified life sciences and diagnostics portfolio, enabling Leica to expand its end-to-end anatomic pathology ecosystem and deliver integrated solutions designed to improve laboratory operational efficiency.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.